

TECHNOLOGY OFFERS

Pipette Device for Delicate Transfer of Tissue in Immunohistochemistry Staining Procedures (P-1295)

Disposable pipette device for the transfer of tissue that prevents undue pressure and subsequent cell damage

EXECUTIVE SUMMARY

As a technical solution a disposable pipette is engineered to have a hole at a specified spot for pressure regulation. This ensures that no under pressure occurs, which might be able to damage the tissue mechanically and/or inhibits the tissue from being sucked into the pipette. For more details regarding the technical solution.



kasto, stock.adobe.com

Category

Research Tools,
Devices,
Microscopy

Indication

Development stage

Prototype

Seeking

Licensing, Commercial partner

BENEFITS

- Disposable pipette device for the transfer of tissue such as in immunohistochemistry (IHC)
- Applicable to all commercially available pipette suction devices
- Particularly useful for paraffin embedded slices smaller than 10 micrometer

TECHNOLOGY BACKGROUND

Staining of tissue is a standard method in biological laboratories, but also in the clinical environment for diagnostics such as immunohistochemistry (IHC). After a certain incubation period the protocol often requires the transfer of the tissue into another staining chamber. This transfer is a critical step since the thickness of the paraffin embedded slices is smaller than 10 micrometers and, therefore, not very resistant against mechanical force so it bears the danger of destroying the biological material. In addition, the slice can be easily sucked into the laboratory pipette during transferring procedure.

DEVELOPMENT STAGE

The prototype of the device has been optimized for different experiments and has already been demonstrated to be successful in staining procedures of IHC.

APPLICATIONS

DKFZ is looking for a commercial partner to produce and distribute the device for biological and medicinal laboratories.

INTELLECTUAL PROPERTY

Patented.

- A German utility model with the title "Absaugvorrichtung für Flüssigkeiten mit Unterdruckbegrenzung" has been granted January 26 in 2017 in Germany as DE202016007102U1.

PUBLICATIONS & REFERENCES

- "Mutant IDH1: An immunotherapeutic target in tumors." published by T. Schuhmacher et al. in Oncoimmunology. 2015 Jan 7;3 (12):e974392.
- "A vaccine targeting mutant IDH1 induces antitumour immunity." Published by T. Schuhmacher et al in Nature. 2014 Aug 21;512(7514):324-7.

DKFZ Contact:

Lana Semykina
Deutsches Krebsforschungszentrum
Innovation Management T010
Email: s.semykina@dkfz.de
Tel.: +49-(0)6221-42-2953
Fax: +49-(0)6221-42-2956

ABOUT THE DKFZ INNOVATION MANAGEMENT

Working at the interface of research and industry, the Innovation Management of the German Cancer Research Center (DKFZ) helps to get new cancer medications, diagnostic tests, and research instruments onto the market as quickly as possible.

The DKFZ with its more than 3,000 employees is the largest biomedical research institution in Germany. At the Center more than 1,300 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg